Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “formulation”

865 pharma patents match "formulation" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 865
Index total 30,257
Page 30 / 37

Quick answer

This filtered view shows 865 pharmaceutical patents matching "formulation" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

865 results for “formulation” · 30,257 patents in full index Clear search

  1. US 8933059

    Natural combination hormone replacement formulations and therapies

    Compass Therapeutics LLC · Granted Jan 13, 2015 · Expires Jan 8, 2035

    granted

  2. US 8920373

    Reduced volume formulation of glatiramer acetate and methods of administration

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  3. US 8921316

    Stable liquid VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  4. US 8916556

    Pharmaceutical formulations comprising neurotrophin mimetics

    The United States of America represented by the Department of Vetran Affairs · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  5. US 8906413

    Drug formulations having reduced abuse potential

    Supernus Pharmaceuticals, Inc. · Granted Dec 9, 2014 · Expires Dec 4, 2034

    granted

  6. US 2014356438

    PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS

    ALLERGAN INC [US] · Granted Dec 4, 2014 · Expires Nov 29, 2034

    granted

  7. US 8900555

    Insulin derivative formulations for pulmonary delivery

    Nektar Therapeutics · Granted Dec 2, 2014 · Expires Nov 27, 2034

    granted

  8. AU 2013258031

    Parenteral esmolol formulation

    AOP ORPHAN PHARMACEUTICALS AG [AT] · Granted Nov 20, 2014 · Expires Nov 15, 2034

    granted

  9. US 8889191

    Sustained-release formulations of topiramate

    Supernus Pharmaceuticals, Inc. · Granted Nov 18, 2014 · Expires Nov 13, 2034

    granted

  10. US 8889672

    Compounds, formulations, and methods of protein kinase C inhibition

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 18, 2014 · Expires Nov 13, 2034

    granted

  11. US 8877248

    Sustained-release formulations of topiramate

    Supernus Pharmaceuticals, Inc. · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted

  12. US 8865210

    Stable dosage formulations of imidazolylalkyl-pyridines

    VANDA PHARMACEUTICALS INC. · Granted Oct 21, 2014 · Expires Oct 16, 2034

    granted

  13. US 8865722

    Wet formulations of aripiprazole

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 21, 2014 · Expires Oct 16, 2034

    granted

  14. US 8846605

    Formulations and methods of use for alpha connexin C-terminal (ACT) peptides

    FIRSTRING RESEARCH, INC. · Granted Sep 30, 2014 · Expires Sep 25, 2034

    granted

  15. US 8846648

    Natural combination hormone replacement formulations and therapies

    Compass Therapeutics LLC · Granted Sep 30, 2014 · Expires Sep 25, 2034

    granted

  16. US 8846649

    Natural combination hormone replacement formulations and therapies

    Compass Therapeutics LLC · Granted Sep 30, 2014 · Expires Sep 25, 2034

    granted

  17. US 2014271721

    PEANUT FORMULATIONS AND USES THEREOF

    ALLERGEN RES CORP [US] · Granted Sep 18, 2014 · Expires Sep 13, 2034

    granted

  18. US 2014271836

    MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION

    ALLERGEN RES CORP [US] · Granted Sep 18, 2014 · Expires Sep 13, 2034

    granted

  19. US 8802107

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted

  20. US 8802628

    Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration

    IRONWOOD PHARMACEUTICALS, INC. · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted

  21. US 8802644

    Lipid formulation

    Tekmira Pharmaceuticals Corporation · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted

  22. US 8795669

    Stabilized formulations containing anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  23. US 8785168

    Formulations for lysosomal enzymes

    BIOMARIN PHARMACEUTICAL INC. · Granted Jul 22, 2014 · Expires Jul 17, 2034

    granted

  24. AU 2012362562

    Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione

    CELGENE CORP [CH] · Granted Jul 17, 2014 · Expires Jul 12, 2034

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.